Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Feb 18, 2021 (filed on Feb 23, 2021)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Warrants to Purchase Common StockNature of Transaction:X - in- or at-the-money exercise# or value acquired/disposed of:368,250Price:$0.01
- Feb 18, 2021 (filed on Feb 23, 2021)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:X - in- or at-the-money exercise# or value acquired/disposed of:368,250Price:$3.45
- Feb 02, 2021 (filed on Feb 17, 2021)Insider Name:Leuthner Brian AOwnership Type:Direct OwnershipSecurities:Stock Option(Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
- Feb 01, 2021 (filed on Feb 03, 2021)Insider Name:DelAversano Robert JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,750Price:--
- Feb 01, 2021 (filed on Feb 02, 2021)Insider Name:O'Connor Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,413Price:$7.71
- Jan 25, 2021 (filed on Jan 27, 2021)Insider Name:China Grand Pharmaceutical & Healthcare Holdings LtdOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:677,839Price:$5.45
- Jan 25, 2021 (filed on Jan 27, 2021)Insider Name:China Grand Pharmaceutical & Healthcare Holdings LtdOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,389,198Price:$5.45
- Nov 20, 2020 (filed on Nov 23, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-80,000Price:$4.92
- Nov 19, 2020 (filed on Nov 20, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-50,000Price:$5.10
- Nov 18, 2020 (filed on Nov 19, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,999Price:$5.24
Filings by filing date
- Feb 18, 2021 (filed on Feb 23, 2021)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Warrants to Purchase Common StockNature of Transaction:X - in- or at-the-money exercise# or value acquired/disposed of:368,250Price:$0.01
- Feb 18, 2021 (filed on Feb 23, 2021)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:X - in- or at-the-money exercise# or value acquired/disposed of:368,250Price:$3.45
- Feb 02, 2021 (filed on Feb 17, 2021)Insider Name:Leuthner Brian AOwnership Type:Direct OwnershipSecurities:Stock Option(Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
- Feb 01, 2021 (filed on Feb 03, 2021)Insider Name:DelAversano Robert JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,750Price:--
- Feb 01, 2021 (filed on Feb 02, 2021)Insider Name:O'Connor Daniel J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,413Price:$7.71
- Jan 25, 2021 (filed on Jan 27, 2021)Insider Name:China Grand Pharmaceutical & Healthcare Holdings LtdOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:677,839Price:$5.45
- Jan 25, 2021 (filed on Jan 27, 2021)Insider Name:China Grand Pharmaceutical & Healthcare Holdings LtdOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,389,198Price:$5.45
- Nov 20, 2020 (filed on Nov 23, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-80,000Price:$4.92
- Nov 19, 2020 (filed on Nov 20, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-50,000Price:$5.10
- Nov 18, 2020 (filed on Nov 19, 2020)Insider Name:Alpha Holdings, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,999Price:$5.24
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 24 N Main St PENNINGTON NJ 08534-2218 |
Tel: | N/A |
Website: | oncosec.com |
IR: | See website |
Key People | ||
Margaret Dalesandro Independent Chairman of the Board | Daniel J. O'Connor President, Chief Executive Officer, Director | Brian A. Leuthner Chief Operating Officer |
Robert J. DelAversano Principal Accounting Officer, Controller | Joe Smith Vice President - Business Development |
Business Overview |
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO). |
Financial Overview |
For the three months ended 31 October 2020, OncoSecMedical Inc revenues was not reported. Net loss increased35% to $13.2M. Higher net loss reflects Research anddevelopment - Balancing val increase of 65% to $8.8M(expense), Stock-based Compensation in R&D increase from$100K to $1M (expense), Stock-based Compensation in SGAincrease from $300K to $900K (expense). |
Employees: | 42 as of Jul 31, 2020 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $162.48M as of Oct 31, 2020 |
Annual revenue (TTM): | $0.00M as of Oct 31, 2020 |
EBITDA (TTM): | -$46.34M as of Oct 31, 2020 |
Net annual income (TTM): | -$45.72M as of Oct 31, 2020 |
Free cash flow (TTM): | -$34.75M as of Oct 31, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 35,405,888 as of Jan 21, 2021 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |